Abstract:OBJECTIVE: To evaluate the safety and efficacy of ampicillin/sulbactum in the treatment of bacterial infections. METHOD: 172 patients with infections were enrolled in a randomized controlled open clinical trial. Two generic products of ampicillin/sulbactum (AMP + SUL) was given intravenously 1.5 ~ 3.0 g each time, three times a day for 7 ~ 10 days. RESULTS: In the randomized controlled study, the clinical efficacy rates of the trialed AMP + SUL and controlled AMP + SUL were 90.8% and 86.2%, the bacterial clearance rates were 88.1% and 81.7%, Adverse drug reactions occurred in 10.8% and 13.8% in the two groups respectively. There were no statistical difference between the two groups with respect to clinical efficacy, bacterial clearance and adverse reaction. The results of the opened clinical trial showed the clinical efficacy rate of trialed APM + SUL were 88.1%, the bacterial eradication were 88.6%, the incidence of adverse drug reactions were 9.5%. CONCLUSION: Ampicillin/sulbactum is a safe and effective combination in treating bacterial infections.

A randomized controlled open study of ampicillin/sulbactum in the treatment of 172 cases with bacterial infections